Cancer Institute A national cancer institute
designated cancer center

Helen M. Blau

Publication Details

  • Epidermal growth factor receptor dimerization monitored in live cells.

    Blakely BT, Rossi FM, Tillotson B, Palmer M, Estelles A, Blau HM. Nat Biotechnol. 2000; 18 (2): 218-22

    We present a method for monitoring receptor dimerization at the membrane of live cells. Chimeric proteins containing the epidermal growth factor (EGF) receptor extracellular and transmembrane domains fused to weakly complementing beta-galactosidase (beta-gal) deletion mutants were expressed in cells in culture. Treatment of the cells with EGF-like compounds for as little as 15 s resulted in chimeric receptor dimerization detectable as beta-gal enzymatic activity. The dose response of chimeric receptors was ligand specific. beta-galactosidase complementation was reversible upon removal of ligand and could be reinduced. Antibodies that block ligand binding inhibited receptor dimerization and beta-gal complementation. These results demonstrate that beta-gal complementation provides a rapid, simple, and sensitive assay for protein interactions and for detecting and monitoring the kinetics of receptor dimerization.

    PubMedID: 10657132

Stanford Medicine Resources:

Footer Links: